SCHEDULE: Intracoastal Capital Discloses 9.99% Stake in Microbot

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Microbot Medical Inc. as of June 30, 2025.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported beneficial ownership of 4,200,951 shares of Microbot Medical Inc. common stock.
• This ownership represents 9.99% of Microbot Medical Inc.'s common stock class.
• The reported stake includes 7,700 shares directly held by Intracoastal Capital LLC and 4,193,251 shares issuable upon the exercise of two warrants (Intracoastal Warrant 1 and Intracoastal Warrant 2).
• The percentage ownership calculation is based on 36,377,812 shares outstanding as of May 12, 2025, plus 1,480,504 shares issued since May 13, 2025, and the exercisable warrant shares.
• Additional warrants (Intracoastal Warrant 2, 3, and 4) held by Intracoastal contain blocker provisions, preventing their exercise if it would result in beneficial ownership exceeding 9.99% or 4.99%, respectively.
• Without these blocker provisions, the reporting persons would beneficially own 7,695,600 shares.
• The shares were acquired and are held for investment purposes and not with the intent to change or influence the control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing indicates a significant, albeit passive, ownership stake by an institutional investor group, which can be viewed as a positive signal of confidence in the company. The presence of blocker provisions suggests a strategic, long-term holding approach without immediate intent to influence control.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor group (Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher) can be interpreted as a vote of confidence in Microbot Medical Inc.
• The presence of blocker provisions in the warrants indicates a strategic approach by the investors to maintain a substantial stake while adhering to regulatory thresholds, suggesting a long-term, passive investment strategy.

Risks

• The filing highlights the existence of blocker provisions in warrants, which, while preventing immediate full exercise, indicate a potential for future dilution if these warrants are exercised up to the permitted thresholds.
• The beneficial ownership includes shares issuable upon warrant exercise, meaning the full 9.99% stake is not entirely composed of currently outstanding common stock, introducing a potential for future share issuance.

Future Outlook

NA

Industry Context

This filing represents a routine disclosure of a significant passive investment by an institutional group in a publicly traded company. Such disclosures are common and indicate that an investor group has accumulated a substantial stake, signaling their belief in the company's long-term prospects within its industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional ownership stake may enhance market confidence and potentially contribute to share price stability.
• Company Management: Awareness of a substantial, passive institutional shareholder group may influence strategic considerations, even without direct control intent.

Key Dates

Recommendation

The filing reveals a substantial passive investment by an institutional group, suggesting confidence in Microbot Medical Inc. However, as a Schedule 13G, it primarily discloses ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The strategic use of blocker provisions indicates a long-term, non-activist stance, making 'hold' appropriate for existing investors, while new investors should await further operational updates.

Keywords

Microbot Medical Inc., MBOT, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, beneficial ownership, common stock, warrants, institutional investor, passive investment, SEC filing